By Matt Grossman

Regeneron Pharmaceuticals Inc. is initiating a Phase 3 trial for its double antibody cocktail to determine whether the cocktail can prevent Covid-19, the Tarrytown, N.Y.-based company said Monday.

The trial will evaluate whether Regeneron's cocktail, called REGN-COV2, can prevent infection among people who have had close exposure to the coronavirus that causes the disease.

Regeneron's trial will enroll 2,000 patients at approximately U.S. 100 sites.

The company has also moved into the Phase 2/3 portion of trials testing the cocktail's ability to treat people who have already contracted Covid-19. That effort will enroll approximately 2,900 patients, including hospitalized and non-hospitalized patients, at 150 sites in the U.S., Brazil, Mexico and Chile.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

July 06, 2020 07:33 ET (11:33 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.
Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Regeneron Pharmaceuticals Charts.